Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-MIBG and 90Y-DOTATOC in Midgut Neuroendocrine Tumors
NCT03044977Phase 1Active, not recruiting
- Start
- May 2017
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of Iobenguane I-131 and yttrium-90 edotreotide in Gastrointestinal neuroendocrine tumor, pheochromocytoma and Paraganglioma (PGL). Started May 2017; status: active, not recruiting.
02
Drugs
Iobenguane I-131yttrium-90 edotreotide
03
Conditions
Gastrointestinal neuroendocrine tumorpheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT03044977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03044977.